A GLP-1 derivative which comprises a modified GLP-1 sequence having: a total of 2-12 amino acid modifications as compared to GLP-1 (SEQ ID No: 1), having the sequence of formula: Xaa 7 -Xaa 8 -Xaa 9 -Gly-Thr-Phe-Thr-Ser-Asp-Xaa 16 -Ser-Xaa 18 -Tyr- Xaa 20 - Glu-Glu-Xaa 23 - Xaa 24 -Xaa 25 -Arg-Xaa 27 -Xaa 28 -Ile-Xaa 30 -Xaa 31 -Leu-Xaa 33 -Xaa 34 -Xaa 35 - Xaa 36 -Xaa 37 -Xaa 38 - Xaa 39 -Xaa 40 - Xaa 41 -R Formula (SEQ ID No: 2) wherein (Xaa 7 - Xaa 8) is (L-histidine-Aib), (desamino-histidine-alanine), or (desamino-histidine-Aib); Xaa 9 is Glu; Xaa 16 is Val, or Leu; Xaa 18 is Ser, Lys, Cys, or Arg; Xaa 20 is Leu, or Lys; Xaa 23 is Gln, Glu, Lys, Cys, or Arg; Xaa 24 is Ala, or Asn; Xaa 25 is Ala, or Val; Xaa 27 is Glu, Ala, or Leu; Xaa 28 is Phe; Xaa 30 is Ala, Glu, Lys, or Arg; Xaa 31 is Trp, Cys, or Lys; Xaa 33 is Val, Cys, or Lys; Xaa 34 is Lys, Cys, Glu, Asn, Dap, or Arg; Xaa 35 is Gly, Arg, Lys, Aib, or absent; Xaa 36 is Arg, Lys, or absent; Xaa 37 is Gly, Aib, Cys, Lys, epsilon-amino-Lys, Pro, Arg, or absent; Xaa 38 is Lys, Glu, Arg, or absent; Xaa 39 is Lys, Arg, or absent; Xaa 40 is Arg, or absent; Xaa 41 is Arg, or absent; and R is amide, or absent; provided that if Xaa 37, Xaa 38, Xaa 39, or Xaa 40 is absent, then each amino acid residue downstream is also absent; and wherein the amino acid at the position equivalent to position 31 of GLP-1 is derivatised with A-B-C-D wherein A- is selected from the group consisting of and wherein the tetrazole ring is optionally N-substituted, and wherein n is selected from the group consisting of 14, 15, 16 17, 18 and 19, p is selected from the group consisting of 10, 11, 12, 13 and 14, and d is selected from the group consisting of 0, 1, 2, 3, 4 and 5, -B- is selected from the group consisting of and wherein x is selected from the group consisting of 0, 1, 2, 3 and 4, and y is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12, -C- is selected from the group consisting of and wherein b and e are each independently selected from the group consisting of 0, 1 and 2, and c and f are each independently selected from the group consisting of 0, 1 and 2 with the proviso that b is 1 or 2 when c is 0, or b is 0 when c is 1 or 2, and e is 1 or 2 when f is 0, or e is 0 when f is 1 or 2, and -D- is attached to said amino acid residue and is a linker, wherein said GLP-1 derivative has a half-life of 40-100 hours after subcutaneous administration in minipigs. a total of 2-12 amino acid modifications as compared to GLP-1 (SEQ ID No: 1), having the sequence of formula: Xaa 7 -Xaa 8 -Xaa 9 -Gly-Thr-Phe-Thr-Ser-Asp-Xaa 16 -Ser-Xaa 18 -Tyr- Xaa 20 - Glu-Glu-Xaa 23 - Xaa 24 -Xaa 25 -Arg-Xaa 27 -Xaa 28 -Ile-Xaa 30 -Xaa 31 -Leu-Xaa 33 -Xaa 34 -Xaa 35 - Xaa 36 -Xaa 37 -Xaa 38 - Xaa 39 -Xaa 40 - Xaa 41 -R Formula (SEQ ID No: 2) wherein (Xaa 7 - Xaa 8) is (L-histidine-Aib), (desamino-histidine-alanine), or (desamino-histidine-Aib); Xaa 9 is Glu; Xaa 16 is Val, or Leu; Xaa 18 is Ser, Lys, Cys, or Arg; Xaa 20 is Leu, or Lys; Xaa 23 is Gln, Glu, Lys, Cys, or Arg; Xaa 24 is Ala, or Asn; Xaa 25 is Ala, or Val; Xaa 27 is Glu, Ala, or Leu; Xaa 28 is Phe; Xaa 30 is Ala, Glu, Lys, or Arg; Xaa 31 is Trp, Cys, or Lys; Xaa 33 is Val, Cys, or Lys; Xaa 34 is Lys, Cys, Glu, Asn, Dap, or Arg; Xaa 35 is Gly, Arg, Lys, Aib, or absent; Xaa 36 is Arg, Lys, or absent; Xaa 37 is Gly, Aib, Cys, Lys, epsilon-amino-Lys, Pro, Arg, or absent; Xaa 38 is Lys, Glu, Arg, or absent; Xaa 39 is Lys, Arg, or absent; Xaa 40 is Arg, or absent; Xaa 41 is Arg, or absent; and R is amide, or absent; provided that if Xaa 37, Xaa 38, Xaa 39, or Xaa 40 is absent, then each amino acid residue downstream is also absent; (Xaa 7 - Xaa 8) is (L-histidine-Aib), (desamino-histidine-alanine), or (desamino-histidine-Aib); Xaa 9 is Glu; Xaa 16 is Val, or Leu; Xaa 18 is Ser, Lys, Cys, or Arg; Xaa 20 is Leu, or Lys; Xaa 23 is Gln, Glu, Lys, Cys, or Arg; Xaa 24 is Ala, or Asn; Xaa 25 is Ala, or Val; Xaa 27 is Glu, Ala, or Leu; Xaa 28 is Phe; Xaa 30 is Ala, Glu, Lys, or Arg; Xaa 31 is Trp, Cys, or Lys; Xaa 33 is Val, Cys, or Lys; Xaa 34 is Lys, Cys, Glu, Asn, Dap, or Arg; Xaa 35 is Gly, Arg, Lys, Aib, or absent; Xaa 36 is Arg, Lys, or absent; Xaa 37 is Gly, Aib, Cys, Lys, epsilon-amino-Lys, Pro, Arg, or absent; Xaa 38 is Lys, Glu, Arg, or absent; Xaa 39 is Lys, Arg, or absent; Xaa 40 is Arg, or absent; Xaa 41 is Arg, or absent; and R is amide, or absent; provided that if Xaa 37, Xaa 38, Xaa 39, or Xaa 40 is absent, then each amino acid residue downstream is also absent; wherein A- is selected from the group consisting of and wherein the tetrazole ring is optionally N-substituted, and wherein n is selected from the group consisting of 14, 15, 16 17, 18 and 19, p is selected from the group consisting of 10, 11, 12, 13 and 14, and d is selected from the group consisting of 0, 1, 2, 3, 4 and 5, -B- is selected from the group consisting of and wherein x is selected from the group consisting of 0, 1, 2, 3 and 4, and y is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12, -C- is selected from the group consisting of and wherein b and e are each independently selected from the group consisting of 0, 1 and 2, and c and f are each independently selected from the group consisting of 0, 1 and 2 with the proviso that b is 1 or 2 when c is 0, or b is 0 when c is 1 or 2, and e is 1 or 2 when f is 0, or e is 0 when f is 1 or 2, and -D- is attached to said amino acid residue and is a linker, wherein said GLP-1 derivative has a half-life of 40-100 hours after subcutaneous administration in minipigs.